Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.68 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.68 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.68 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.68 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.68 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.68 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.68 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.68 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 5/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10913404 | 1.00 | HDAC8 (0.68) | HDAC8HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL7443883 | 0.98 | HDAC8 (0.65) | HDAC8HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL2084857 | 0.93 | ALDH1A1 (0.59) | HDAC8HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL29740524 | 0.93 | ALDH1A1 (0.59) | HDAC8HDAC3HDAC4HDAC1HDAC7 | |
| Ethylene SCHEMBL9101813 | 0.90 | ALDH1A1 (0.56) | HDAC8HDAC3HDAC4HDAC1HDAC7 | |
| Ethylene Glycol SCHEMBL7141967 | 0.89 | ALDH1A1 (0.55) | HDAC8HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL15500771 | 0.86 | ALDH1A1 (0.71) | HDAC8HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL10655522 | 0.86 | HDAC8 (0.62) | HDAC8HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL133683 | 0.86 | KMT2A (0.59) | HDAC8HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL24687436 | 0.85 | HDAC8 (0.69) | HDAC8HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160376591-A1 | iRNA AGENTS WITH BIOCLEAVABLE TETHERS | BANK OF AMERICA, N.A. | 2016-12-29 | — | — | US | disclosed |
| US-9476045-B2 | iRNA agents with biocleavable tethers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-10-25 | — | — | US | disclosed |
| US-9476045-B2 | iRNA agents with biocleavable tethers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-10-25 | — | — | US | disclosed |
| US-9453222-B2 | Ligand-conjugated monomers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150191726-A1 | LIGAND-CONJUGATED MONOMERS | BANK OF AMERICA, N.A. | 2015-07-09 | — | — | US | disclosed |
| US-20150073133-A1 | iRNA AGENTS WITH BIOCLEAVABLE TETHERS | BANK OF AMERICA, N.A. | 2015-03-12 | — | — | US | disclosed |
| US-8865677-B2 | iRNA agents with biocleavable tethers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-8865677-B2 | iRNA agents with biocleavable tethers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20130281685-A1 | iRNA AGENTS WITH BIOCLEAVABLE TETHERS | BANK OF AMERICA, N.A. | 2013-10-24 | — | — | US | disclosed |
| US-20130281685-A1 | iRNA AGENTS WITH BIOCLEAVABLE TETHERS | BANK OF AMERICA, N.A. | 2013-10-24 | — | — | US | disclosed |
| US-8426377-B2 | iRNA agents with biocleavable tethers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8017762-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-20100267941-A1 | IRNA AGENTS WITH BIOCLEAVABLE TETHERS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-7723509-B2 | Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue, for drug delivery to target tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; biodrugs | ALNYLAM PHARMACEUTICALS (US) | 2010-05-25 | — | — | US | disclosed |
| US-20100076056-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-RE32868-E | Antihyperlipidemic compositions | RESEARCH CORPORATION (US) | 1989-02-14 | — | — | US | disclosed |
| US-4395417-A | Antihyperlipidemic compositions | RESEARCH CORPORATION (US) | 1983-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191726-A1 | LIGAND-CONJUGATED MONOMERS | TNFSF11, BCDIN3D, CD40LG | HDAC8 2205/4885HDAC3 2140/4885HDAC4 3313/4885 |
| US-20100076056-A1 | MODIFIED iRNA AGENTS | LDLR, RNASE1, SARNP | HDAC8 434/4885HDAC3 911/4885HDAC4 1794/4885 |
| US-20100267941-A1 | IRNA AGENTS WITH BIOCLEAVABLE TETHERS | DCLRE1A, PARP1, LIG1 | HDAC8 477/4885HDAC3 1538/4885HDAC4 2146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.